The BRAF-mutant human melanoma cell lines A375 and SK-Mel28 were purchased from the European Collection of Cell Cultures (Salisbury, UK) and American Type Culture Collection (ATCC, Manassas, VA), respectively. The cells were cultured in BioWhittaker™ RPMI-1640 medium (LONZA, Verviers, Belgium) supplemented with 10% fetal bovine serum (Sigma-Aldrich, St. Louis, MO), 2 mM BioWhittaker™ L-glutamine (LONZA), and 50 μg/ml BioWhittaker™ gentamicin (LONZA) (hereafter referred to as complete medium, CM).
The dabrafenib-resistant A375R and SK-Mel28R cell lines were generated in our laboratory by growing A375 and SK-Mel28 cells in gradually increasing concentrations of the drug (up to 1.5 μM) [27 (link), 28 (link)]. A375R and SK-Mel28R cell lines were maintained in CM supplemented with 1.5 μM dabrafenib. The two pair of sensitive/resistant cell lines were authenticated by STR profiling (BMR genomics, Padova, Italy).
The dabrafenib-resistant A375R and SK-Mel28R cell lines were generated in our laboratory by growing A375 and SK-Mel28 cells in gradually increasing concentrations of the drug (up to 1.5 μM) [27 (link), 28 (link)]. A375R and SK-Mel28R cell lines were maintained in CM supplemented with 1.5 μM dabrafenib. The two pair of sensitive/resistant cell lines were authenticated by STR profiling (BMR genomics, Padova, Italy).
Free full text: Click here
